Aurobindo Pharma, one of India’s leading pharmaceutical giants, has issued a formal clarification regarding recent media reports suggesting its imminent acquisition of Prague-based generic drugmaker Zentiva. The news, which has stirred significant market interest and led to a 4% dip in Aurobindo’s share price, claimed that the company was closing in on a $5–5.5 billion deal—potentially the largest-ever acquisition by an Indian pharma firm.
In its statement, Aurobindo Pharma acknowledged the speculation but emphasized that no binding agreement has been finalized. “While we continuously evaluate strategic opportunities to enhance our global footprint, we wish to clarify that no definitive agreement has been signed with Zentiva or its parent company Advent International,” the company said. The clarification comes amid heightened investor scrutiny and media coverage that positioned Aurobindo as the frontrunner in a competitive bidding process that reportedly includes U.S. private equity firm GTCR.
The Zentiva Opportunity
Zentiva, headquartered in Prague, is a well-established player in the European generics market. Owned by Advent International since 2018, the company has a strong presence in Eastern Europe, particularly in the Czech Republic, Romania, and Slovakia. These regions are considered fertile ground for biosimilars, especially as patents for major prescription drugs continue to expire.
According to reports, Zentiva generated revenues of €1.7 billion ($1.98 billion) in calendar year 2024, with an EBITDA of €400 million ($467 million). The acquisition, if completed, would significantly bolster Aurobindo’s European operations, which already lead among Indian pharma peers in terms of regional revenue share.
Market Reaction & Financial Snapshot
Following the news reports, Aurobindo Pharma’s stock fell over 4% to ₹1,039 on August 20, reflecting investor caution amid uncertainty over deal finalization. The company’s stock has declined by 21% year-to-date, underperforming the benchmark Nifty 50 index, which saw a modest 2% rise over the same period1.
In its Q1 FY26 earnings report, Aurobindo posted a consolidated net profit of ₹824 crore, down 10.2% year-on-year. Revenue from operations rose 4% to ₹7,868 crore, while operating EBITDA stood at ₹1,603 crore. The EBITDA margin slipped to 20.4% from 21.4% a year earlier. Notably, while U.S. formulations revenue declined 1.9% due to destocking and seasonal headwinds, European formulations surged 18% year-on-year to ₹2,338 crore, underscoring the strategic importance of the region1.
Strategic Implications
Industry analysts suggest that the Zentiva acquisition could be transformative for Aurobindo, allowing it to scale its biosimilars portfolio and deepen its access to government-led procurement markets in Eastern Europe. Unlike the U.S., where price erosion is a persistent challenge, Eastern European markets offer more stable returns due to centralized healthcare spending.
If the deal materializes, it would eclipse previous landmark transactions such as Daiichi Sankyo’s $3.2 billion stake acquisition in Ranbaxy (2014) and Biocon Biologics’ $3.3 billion buyout of Viatris’ biosimilars business.
What Comes Next?
Sources close to the matter indicate that negotiations are in advanced stages, with binding offers already submitted. A formal announcement could be expected within the next few weeks, although Aurobindo’s clarification suggests that the final contours of the deal are still being shaped.
Meanwhile, Advent International has reportedly engaged Goldman Sachs and PJT Partners to explore exit options for Zentiva, having held the asset for seven years. The competitive bidding process has seen interest from multiple financial investors and pharma companies globally.
Conclusion
While Aurobindo Pharma’s clarification tempers immediate expectations, the potential Zentiva acquisition remains a high-stakes development in the global pharmaceutical landscape. Whether the deal closes or not, it signals Aurobindo’s ambition to expand its European footprint and capitalize on the growing biosimilars market.
Investors and industry watchers will be keenly awaiting further updates, as the outcome could reshape the trajectory of Indian pharma on the global stage.
Sources: Moneycontrol, Economic Times
